Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Operating Leases: 2023-2025

  • China SXT Pharmaceuticals' Operating Leases fell 53.38% to $85,161 in Q3 2025 from the same period last year, while for Sep 2025 it was $85,161, marking a year-over-year decrease of 53.38%. This contributed to the annual value of $176,648 for FY2025, which is 25.10% down from last year.
  • According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Operating Leases is $85,161, which was down 51.79% from $176,648 recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Operating Leases high stood at $306,050 for Q1 2023, and its period low was $85,161 during Q3 2025.
  • Over the past 3 years, China SXT Pharmaceuticals' median Operating Leases value was $193,802 (recorded in 2023), while the average stood at $198,552.
  • Data for China SXT Pharmaceuticals' Operating Leases shows a maximum YoY plummeted of 53.38% (in 2025) over the last 5 years.
  • Over the past 3 years, China SXT Pharmaceuticals' Operating Leases (Quarterly) stood at $204,937 in 2023, then declined by 10.87% to $182,667 in 2024, then tumbled by 53.38% to $85,161 in 2025.
  • Its Operating Leases stands at $85,161 for Q3 2025, versus $176,648 for Q1 2025 and $182,667 for Q3 2024.